FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
25 sept. 2023 08h30 HE
|
Coherus BioSciences, Inc.
– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL – – No additional...
Coherus BioSciences Announces New Employment Inducement Grants
22 sept. 2023 21h00 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective September 20, 2023, the compensation...
Coherus Completes Surface Oncology Acquisition
08 sept. 2023 09h05 HE
|
Coherus BioSciences, Inc.
– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment – – I-O combinations will...
Coherus BioSciences to Participate at Upcoming September Investor Conferences
01 sept. 2023 16h01 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor...
Coherus BioSciences Announces New Employment Inducement Grants
22 août 2023 17h35 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 20, 2023, the compensation...
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
02 août 2023 16h01 HE
|
Coherus BioSciences, Inc.
– Net revenue rose 81% from prior quarter to $58.7 million –– CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter –– UDENYCA® autoinjector launched in late May, and YUSIMRY™...
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
26 juil. 2023 16h05 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market...
Coherus BioSciences Announces New Employment Inducement Grants
21 juil. 2023 17h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., July 21, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 20, 2023, the compensation committee...
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
20 juil. 2023 16h04 HE
|
Coherus BioSciences, Inc.
– Recognized biopharma commercialization and market access leader to support Coherus’ strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) --...
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
13 juil. 2023 08h30 HE
|
Coherus BioSciences, Inc.
First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of more than 85% compared to HumiraInnovative...